SCHEMBL465737

SCHEMBL465737

COC(=O)c1cccc(C(=O)O)c1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
HSD17B10 Q99714 3/20 0.58
CFTR P13569 1/20 0.58
CASP7 P55210 2/20 0.55
G6PD P11413 1/20 0.55
CASP6 P55212 1/20 0.55
MAPT P10636 3/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 4/20 0.49
HPGD P15428 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA5A P35218 1/20 0.47
KDM4E B2RXH2 4/20 0.47
ATM Q13315 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31634613 1.00 ALDH1A1 (0.58) ALDH1A1HSD17B10CFTRCASP7G6PD
SCHEMBL2895994 0.92 ALDH1A1 (0.67) ALDH1A1HSD17B10CFTRCASP7MAPT
SCHEMBL19991850 0.88 ALDH1A1 (0.50) ALDH1A1HSD17B10CFTRCASP7G6PD
Methoxymethane SCHEMBL5903652 0.88 G6PD (0.63) ALDH1A1HSD17B10CFTRCASP7G6PD
SCHEMBL14828745 0.85 ALDH1A1 (0.58) ALDH1A1HSD17B10CFTRCASP7MAPT
SCHEMBL28957307 0.85 ALDH1A1 (0.58) ALDH1A1HSD17B10CFTRCASP7MAPT
SCHEMBL526919 0.83 G6PD (0.74) ALDH1A1HSD17B10CASP7G6PDCASP6
SCHEMBL27475798 0.83 ALDH1A1 (0.56) ALDH1A1HSD17B10CFTRCASP7MAPT
SCHEMBL31589985 0.82 ALDH1A1 (0.71) ALDH1A1HSD17B10CFTRCASP7MAPT
SCHEMBL505249 0.82 ALDH1A1 (0.71) ALDH1A1HSD17B10CFTRCASP7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118004999-A Porous hard carbon composite material prepared by interface method and preparation method thereof 云南坤天新能源有限公司 2024-05-10 CN claimed
WO-2024150597-A1 THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT JNC株式会社 2024-07-18 WO disclosed
CN-118004999-A Porous hard carbon composite material prepared by interface method and preparation method thereof 云南坤天新能源有限公司 2024-05-10 CN disclosed
CN-118004999-A Porous hard carbon composite material prepared by interface method and preparation method thereof 云南坤天新能源有限公司 2024-05-10 CN disclosed
EP-3619205-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2022-04-06 EP disclosed
US-10954252-B1 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2021-03-23 US disclosed
EP-3619205-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-03-11 EP disclosed
WO-2018203235-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-11-08 WO disclosed
US-9326986-B2 Quinazolinone, quinolone and related analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2016-05-03 US disclosed
US-9326986-B2 Quinazolinone, quinolone and related analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2016-05-03 US disclosed
WO-2012059442-A2 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2012-05-10 WO disclosed
WO-2012059442-A2 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2012-05-10 WO disclosed
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed
CN-102227420-A Quinazolinone, quinolone and related analogs as sirtuin modulators SIRTRIS PHARMACEUTICALS INC 2011-10-26 CN disclosed
EP-2344475-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-07-20 EP disclosed
WO-2010037129-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS INC. (US) 2010-04-01 WO disclosed
WO-2010037129-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS INC. (US) 2010-04-01 WO disclosed
WO-2007028789-A1 QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954252-B1 Inhibitors of human immunodeficiency virus replication EIF2AK2, REV1, POLR2E ALDH1A1 2628/4885HSD17B10 2079/4885CFTR 888/4885
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 ALDH1A1 1976/4885HSD17B10 1341/4885CFTR 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.